臍帶間充質(zhì)干細(xì)胞治療狼瘡性腎炎的作用及機(jī)制
[Abstract]:[Objective] Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease involving multiple organs with unclear etiology and pathogenesis. The most common clinical manifestation of SLE is lupus nephritis (LN), which accounts for 60% to 70% of SLE deaths. The etiology and pathogenesis of lupus nephritis are still unknown. It is not clear that the imbalance of cytokine network or abnormal expression of cytokines is one of the important factors in the pathogenesis of LN. Mesenchymal stem cells (MSC) have a certain effect on the treatment of LN. A number of experiments have suggested that the expression of osteopontin (OPN) in blood or urine is closely related to the degree of LN injury and the changes of LN condition. It is important for the diagnosis and treatment of LN. Objective: To investigate the clinical efficacy and mechanism of umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) in the treatment of LN, and to explore the role and mechanism of osteopontin (OPN) in the treatment of LN by UC-MSC. [Methods] 1. HUC-MSC or placebo replacement were given to 13 patients with LN and WHO type III/IV. The levels of OPN, AP-1, Sp-1, NF-KB, MMP-2 and MMP-9 in serum of two groups of LN patients were measured by ELISA. 2. UC-MSCs of IC iron oxide polylysine group and control group (not infused with HUC-MSCs), the distribution of UC-MSCs was observed by MRI scan after treatment; (2) The changes of body weight, urinary protein and related immunological indexes were observed before and after treatment in two groups of MRL/lpr mice; (3) The slowness of GFP carrying the target gene green fluorescent protein (GFP) was observed. Human umbilical cord stem cells were labeled and injected into MRL/lpr lupus mice to observe the effect of UC-MSCs transplantation on OPN expression in kidney of MRL/lpr mice. Twelve 22-week-old normal C57BL/6 mice were injected with PBS as normal control group.The expression of OPN,AP-1 and Sp-1 in renal tissues of HUC-MSCs transplantation treated MRL/lpr mice and control group were detected by RT-qPCR,Western-blot and immunohistochemistry. The expression levels of OPN, MMP-2 and MMP-9 in serum of patients with LN after HUC-MSC transplantation were lower than those of the control group 2 months later. After 6 months of HUC-MSC transplantation, the expression levels of OPN, MMP-2 and MMP-9 in the treatment group were significantly lower than those in the control group. Serum levels of transcription factors AP-1, SP-1 and NF-kappa B/P65: 6 months after treatment, compared with 2 months after treatment, the expression levels of AP-1, SP-1 and NF-kappa B in the treatment group showed a downward trend. 3. Compared with HUC-MSC transplantation in lupus mice treated with MRL/lpr, 24 hours urinary protein and serum protein levels in the treatment group were found. HUC-MSC transplantation significantly reduced the expression of OPN, MMP-2 and MMP-9 in the serum of MRL/lpr mice (P 0.05). The expression levels of transcription factors AP-1, SP-1 and NF-kappa B/p65 in the serum were significantly decreased (P 0.05). 5. HUC-MSC transplantation significantly reduced the expression of MRL/lpr wolf. Expression of OPN, MMP-2, MMP-9 and transcription factors AP-1, SP-1 and NF-kappa B in renal tissues of mice with lupus erythematosus. 6. HUC-MSC transplantation significantly decreased the expression of OPN, MMP-2, MMP-9 and transcription factors AP-1, SP-1 and NF-kappa B in glomerular mesangial cells, renal tubules of mice with lupus erythematosus. The expression levels of OPN, AP-1, SP-1, NF-kappa B/P65, MMP-2 and MMP-9 in LN patients have a certain effect on the treatment of LN patients; HUC-MSC transplantation has a certain effect on the treatment of lupus nephritis in MRL/lpr mice; the expression level of OPN in serum of treatment group is significantly reduced, and the expression of transcription factors AP-1, SP-1, MMP-2, MMP-9 and NF-kappa B/p65 in protein and RNA. These results suggest that HUC-MSC transplantation may reduce the expression of transcription factors AP-1, SP-1 and NF-kappa B, inhibit the expression of OPN. The decrease of OPN expression inhibits the activation of NF-kappa B pathway, thereby reducing the expression of MMP-2 and MMP-9 downstream of the pathway. This study provides a basis for HUC-MSC transplantation in the treatment of LN.
【學(xué)位授予單位】:昆明醫(yī)科大學(xué)
【學(xué)位級別】:博士
【學(xué)位授予年份】:2016
【分類號】:R593.242
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 唐幫麗;鄧丹琪;張佩蓮;郭蕓;周曉鴻;曹文婷;劉沐蕓;胡祥;;臍帶間充質(zhì)干細(xì)胞移植治療狼瘡性腎炎的療效與機(jī)制[J];昆明醫(yī)科大學(xué)學(xué)報(bào);2016年07期
2 羅妙旋;米向斌;張?zhí)玫?邱賢文;張亞杰;;骨橋蛋白在SLE腎損害Th17細(xì)胞異常中的作用[J];安徽醫(yī)科大學(xué)學(xué)報(bào);2015年08期
3 Eleuterio Lombardo;Tom van der Poll;Olga Dela Rosa;Wilfried Dalemans;;Mesenchymal stem cells as a therapeutic tool to treat sepsis[J];World Journal of Stem Cells;2015年02期
4 李海端;李建華;;狼瘡腎炎的藥物治療進(jìn)展[J];醫(yī)學(xué)綜述;2014年24期
5 祁秋干;紀(jì)娜;史強(qiáng);祁巖超;;臍血間充質(zhì)干細(xì)胞治療嚴(yán)重性系統(tǒng)性紅斑狼瘡的臨床療效初探[J];中華細(xì)胞與干細(xì)胞雜志(電子版);2014年03期
6 唐幫麗;鄧丹琪;;間充質(zhì)干細(xì)胞移植治療自身免疫性疾病的進(jìn)展[J];臨床皮膚科雜志;2013年01期
7 周蕾;杜曉敏;張宗芳;王坤坤;;系統(tǒng)性紅斑狼瘡患者血清骨橋蛋白檢測及意義[J];天津醫(yī)藥;2011年11期
8 張旭;;風(fēng)濕免疫性疾病患者血清骨橋蛋白的檢測及意義[J];中國民族民間醫(yī)藥;2010年16期
9 劉博;趙鋮;;間充質(zhì)干細(xì)胞在系統(tǒng)性紅斑狼瘡治療中的研究進(jìn)展[J];內(nèi)科;2010年02期
10 龔穎;鐘清;譙林;;系統(tǒng)性紅斑狼瘡患者血清骨橋蛋白表達(dá)的變化及其臨床意義[J];重慶醫(yī)科大學(xué)學(xué)報(bào);2008年11期
相關(guān)碩士學(xué)位論文 前2條
1 薛曉菲;狼瘡性腎炎活動性病變與足細(xì)胞損傷關(guān)系的研究[D];青島大學(xué);2013年
2 杜曉敏;血清骨橋蛋白水平與系統(tǒng)性紅斑狼瘡疾病活動性及臟器損害的相關(guān)性研究[D];天津醫(yī)科大學(xué);2010年
,本文編號:2222829
本文鏈接:http://www.lk138.cn/yixuelunwen/mjlw/2222829.html